Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 78,127 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 78,127 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the transaction, the chief executive officer now directly owns 109,956 shares in the company, valued at approximately $3,256,896.72. The trade was a 41.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44.
• On Friday, September 20th, Andrew Dudum sold 45,767 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.33, for a total value of $747,375.11.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $28.55 on Thursday. Hims & Hers Health, Inc. has a 1-year low of $8.09 and a 1-year high of $35.02. The firm has a market cap of $6.24 billion, a PE ratio of 64.89 and a beta of 1.25. The company has a 50-day moving average of $25.46 and a two-hundred day moving average of $21.19.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) EPS. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research report on Tuesday. They issued an “overweight” rating and a $42.00 target price for the company. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Finally, Piper Sandler reissued a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus price target of $22.80.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its holdings in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the period. State Street Corp lifted its position in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after purchasing an additional 206,078 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares during the period. Wellington Management Group LLP grew its holdings in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after buying an additional 218,566 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.